eligibility_summary
Inclusion: ≥18, primary invasive breast cancer with measurable disease (RECIST 1.1), ECOG 0–1, adequate hematologic, hepatic, renal function, CrCl ≥50. Disease: cT2–T4 or node‑positive, or cT1cN0 if HR−, HER2+, or Ki‑67>20%, bilateral allowed with target side set, OFS allowed. Exclusion: pregnant/lactinating, distant mets, neuropathy, severe cardiopulmonary/hepatic/renal disease or active infection (incl HIV), allergy, thromboembolism ≤6 mo, other malignancy (exceptions), investigator judgment.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
NCT06510465 (NeoURANIA) tests neoadjuvant combinations in breast cancer. Interventions: 1) Utidelone (UTD1) – a non-taxane epothilone analog, microtubule-stabilizing cytotoxic that promotes tubulin polymerization, causing mitotic arrest and apoptosis. 2) Cisplatin – a platinum chemotherapeutic that forms DNA intra-/interstrand crosslinks, blocking replication/transcription and triggering apoptosis. In HER2+ cohort add: 3) Trastuzumab – anti-HER2 IgG1 mAb binding domain IV, inhibits HER2 signaling and mediates ADCC. 4) Pertuzumab – anti-HER2 IgG1 mAb binding domain II, blocks HER2 dimerization (esp. HER2/HER3). Target cells/pathways: rapidly dividing breast cancer cells, microtubule dynamics/mitotic spindle, DNA damage response/repair pathways, HER2/ERBB signaling with downstream PI3K/AKT and MAPK, immune effector engagement via ADCC in HER2+ tumors.